Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 2 of 4 (50%) have an AI response strategy ready • 1 patents granted in the last 365 days
Spacecraft Seven LLC has 4 pending office actions in Biotechnology & Pharmaceuticals. Those matters involve 4 distinct examiners and 4 distinct art units, so the docket spans separate technical and examination assignments.
MONTANARI, DAVID A is the busiest examiner, with 1 pending matter. Counsel should manage the matters independently and avoid assuming that one examiner’s approach governs the full portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTANARI, DAVID A | 1 | 64.7% | +49.4% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 16.7% | +40.0% |
| MCLEOD, AFRICA MHAIRIE | 1 | 58.6% | +58.1% |
| CONNORS, ALEXANDRA F | 1 | 23.9% | +43.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019393 | ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF | MCLEOD, AFRICA MHAIRIE | 8d overdue |
| 18019396 | CSRP3 (CYSTEINE AND GLYCINE RICH PROTEIN 3) GENE THERAPY | SPENCER, ANDREA LYNNE MORRIS | — |
| 17430107 | GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE | CONNORS, ALEXANDRA F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18019393 | ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF | MCLEOD, AFRICA MHAIRIE | 8d overdue |
| 18265421 | TREATMENT OF DANON DISEASE | MONTANARI, DAVID A | 34d |
| 18019396 | CSRP3 (CYSTEINE AND GLYCINE RICH PROTEIN 3) GENE THERAPY | SPENCER, ANDREA LYNNE MORRIS | — |
| 17430107 | GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE | CONNORS, ALEXANDRA F | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1631 | 1 |
| 1635 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18265421 | TREATMENT OF DANON DISEASE | MONTANARI, DAVID A | 1632 | §102 | Final Rejection | 34d | AI Ready | Jun 05, 2023 |
| 18019396 | CSRP3 (CYSTEINE AND GLYCINE RICH PROTEIN 3) GENE THERAPY | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Final Rejection | — | Pending | Feb 02, 2023 |
| 18019393 | ADENO-ASSOCIATED VIRAL VECTOR FOR GLUT1 EXPRESSION AND USES THEREOF | MCLEOD, AFRICA MHAIRIE | 1635 | §103§112 | Final Rejection | 8d overdue | AI Ready | Feb 02, 2023 |
| 17430107 | GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE | CONNORS, ALEXANDRA F | 1634 | §103 | Final Rejection | — | Pending | Aug 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSpacecraft Seven LLC has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.
David A Montanari has the most, with 1 of Spacecraft Seven LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.